arrow
W

Wolfgang Wick

University Hospital Heidelberg
H指数:142
被引数:9.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Decoding the regulatory programs governing glioblastoma plasticity

解码调控胶质母细胞瘤可塑性的调控程序

Nature
IF48.5
2026-11-040
OAAI
Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial

作者更正: 新诊断的星形细胞瘤中的IDH1-mutant疫苗: 多中心,单臂,开放标签,人类第一阶段NOA16试验的最终分析

2026-08-030
OAAI
Distinct molecular subgroups in pediatric and young-onset meningiomas require age-adapted risk stratification

儿童及年轻起病型脑膜瘤存在不同的分子亚群,需采用年龄适应性的风险分层策略

2026-07-140
OAAI
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial

IDH1突变疫苗在新诊断星形细胞瘤中的应用:多中心、单臂、开放标签、首次人体1期NOA16试验的最终分析

2026-07-010
OAAI
Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes

Hetairos是一种基于组织学的人工智能模型,用于预测中枢神经系统肿瘤甲基化亚型

2026-06-100
OAAI
Employing nanopore sequencing on FFPE-derived DNA for CNS tumor diagnostics

采用纳米孔测序技术对FFPE来源的DNA进行中枢神经系统肿瘤诊断

2025-11-060
OAAI
Clinical Presentation, Management and Outcome of Tumor inflammation-associated neurotoxicity (TIAN) in CNS lymphoma treated with CD19-CAR T-cell therapy

肿瘤炎症相关神经毒性(TIAN)在经CD19-CAR T细胞疗法治疗的CNS淋巴瘤中的临床表现、管理与转归

2025-11-010
OAAI
Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

与接受vorasidenib或安慰剂治疗的Grade 2,异柠檬酸脱氢酶1/2突变(mIDH1/2)胶质瘤患者中,体素(3D)评估相较于传统双向(2D)评估在INDIGO III期试验中的比较

2025-11-010
OAAI
Distinct epigenetic and transcriptional profiles of Epstein-Barr virus (EBV) positive and negative primary CNS lymphomas

EBV阳性与阴性原发性中枢神经系统淋巴瘤的表观遗传和转录谱存在差异

2025-11-010
OAAI
Hetairos enables AI-based histopathological classification of CNS tumours

Hetairos 实现了基于 AI 的 CNS 肿瘤组织病理学分类

2025-11-010
OAAI
Health-Related Quality of Life in Molecular Glioma Subtypes: A Pooled Analysis from 16 Randomized Trials

分子胶质瘤亚型的健康相关生活质量:一项来自16项随机试验的合并分析

2025-11-010
OAAI
PROGNOSTIC AND PREDICTIVE MARKERS FOR OUTCOME IN PATIENTS WITH IDHMT TUMORS TREATED IN THE EORTC CATNON TRIAL ON ADJUVANT AND/OR CONCURRENT TEMOZOLOMIDE IN ANAPLASTIC ASTROCYTOMA

IDHMT肿瘤患者在接受EORTC CATNON试验中辅助和/或同步替莫唑胺治疗的间变性星形细胞瘤中的预后和预测性生物标志物

2025-11-010
OAAI
MACHINE LEARNING AND MULTI-OMIC ANALYSIS IDENTIFY A MICROENVIRONMENT-DRIVEN MENINGIOMA RISK CONTINUUM UNDERLYING MOLECULAR CLASSIFICATIONS

机器学习和多组学分析识别出一种由微环境驱动的、与分子分类相关的脑膜瘤风险连续体

2025-11-010
PRE
Meningioma brain-invasion is linked to inflammatory induced tumor-neuronal connectivity

脑膜瘤的脑内浸润与炎症诱导的肿瘤-神经元连接有关

2025-11-010
OAAI
Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

体积肿瘤生长率(TGR)建模预测了在INDIGO三期试验中,接受vorasidenib或安慰剂治疗的Grade 2、异柠檬酸脱氢酶1/2突变(mIDH1/2)胶质瘤患者的临床结局。

2025-11-010
OAAI
Advancing CNS tumor diagnostics with expanded DNA methylation-based classification

Sill M, Schrimpf D, Patel A, Sturm D, Jäger N, Sievers P, et al. 推进中枢神经系统肿瘤诊断,扩展基于DNA甲基化的分类方法。medRxiv. (2025). doi: 10.1093/neuonc/noaf201.1012

2025-11-010
OAAI
A MULTI-MODAL SINGLE-CELL AND SPATIAL TRANSCRIPTOMIC ATLAS REVEALS GENE-PROGRAM AND NEIGHBOURHOOD DRIVERS OF MENINGIOMA MALIGNISATION

多模态单细胞与空间转录组图谱揭示脑膜瘤恶化的基因程序和邻域驱动因素

2025-11-010
OAAI
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial

Vorasidenib在IDH1突变或IDH2突变低级别胶质瘤(INDIGO):一项随机、双盲、安慰剂对照、III期试验的次要和探索性终点

2025-10-290
PRE
DISTINCT EPIGENETIC AND TRANSCRIPTIONAL PROFILES OF EPSTEIN-BARR VIRUS (EBV) POSITIVE AND NEGATIVE PRIMARY CNS LYMPHOMAS

EBV阳性与阴性原发性CNS淋巴瘤的差异性表观遗传和转录特征

2025-10-010
OAAI